Altimmune, Inc. (LON: 0A4C)

Market Cap	400.78M
Revenue (ttm)	38.80K
Net Income (ttm)	-77.24M
Shares Out	n/a
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,573
Average Volume	8,848
Open	6.81
Previous Close	6.93
Day's Range	6.79 - 6.99
52-Week Range	4.25 - 11.84
Beta	n/a
RSI	42.80
Earnings Date	Feb 28, 2025

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 59
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4C

Financial Performance

Financial numbers in USD